Skip to main content
. Author manuscript; available in PMC: 2009 Sep 28.
Published in final edited form as: Cancer Chemother Pharmacol. 2008 May 29;63(4):615–625. doi: 10.1007/s00280-008-0774-y

Fig. 2.

Fig. 2

Plasma Concentrations of 10058-F4 versus time in C B-17 SCID mice bearing PC-3 or DU145 xenografts treated i.v. with 20 mg/kg 10058-F4. Symbols are the mean ± standard deviation. The lines are the predicted fits obtained using the two compartment, open, linear model